Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1617-1626

  De Martin, Sara ^a   Gabbia, Daniela ^a   Albertin, Giovanna ^a   Sfriso, Maria Martina ^a   Mescoli, Claudia ^a   Albertoni, Laura ^a   Paliuri, Giovanna ^a   Bova, Sergio ^a   Palatini, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; MESSENGER RNA; PREGNANE X RECEPTOR; CARBON TETRACHLORIDE; CYP3A1 PROTEIN, RAT; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 3A; STEROID RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RNA ANALYSIS; RNA STABILITY; STEADY STATE; TRANSCRIPTION REGULATION; VALIDATION STUDY; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; EXPERIMENTAL LIVER CIRRHOSIS; LIVER MICROSOME; METABOLISM;

ANIMALS; CARBON TETRACHLORIDE; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; ENZYME INDUCTION; GENE EXPRESSION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICROSOMES, LIVER; RATS; RECEPTORS, STEROID;

EID: 84907434105     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058511     Document Type: Article

References (53)

1. Albertin G, Rucinski M, Carraro G, Forneris M, Andreis P, Malendowicz LK, and Nussdorfer GG (2005) Adrenomedullin and vascular endothelium growth factor genes are overexpressed in the regenerating rat adrenal cortex, and AM and VEGF reciprocally enhance their mRNA expression in cultured rat adrenocortical cells. Int J Mol Med 16:431-435.
2. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
3. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703-1712.
4. Choudhuri S, Zhang XJ, Waskiewicz MJ, and Thomas PE (1995) Differential regulation of cytochrome P450 3A1 and P450 3A2 in rat liver following dexamethasone treatment. J Biochem Toxicol 10:299-307.
5. Chovan JP, Ring SC, Yu E, and Baldino JP (2007) Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459-473.
6. Cooper KO, Reik LM, Jayyosi Z, Bandiera S, Kelley M, Ryan DE, Daniel R, McCluskey SA, Levin W, and Thomas PE (1993) Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch Biochem Biophys 301:345-354.
7. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
8. Ennulat D, Walker D, Clemo F, Magid-Slav M, Ledieu D, Graham M, Botts S, and Boone L (2010) Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man. Toxicol Pathol 38:810-828.
9. Farrell GC and Zaluzny L (1984) Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. Aust J Exp Biol Med Sci 62:291-301.
10. Floreani M, Gabbia D, Barbierato M, De Martin S, and Palatini P (2012) Differential inducing effect of benzo[a]pyrene on gene expression and enzyme activity of cytochromes P450 1A1 and 1A2 in Sprague-Dawley and Wistar rats. Drug Metab Pharmacokinet 27:640-652.
11. Floreani M, De Martin S, Gabbia D, Barbierato M, Nassi A, Mescoli C, Orlando R, Bova S, Angeli P, and Gola E, et al. (2013) Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes. PLoS One 8:e61983.
12. Franc MA, Pohjanvirta R, Tuomisto J, and Okey AB (2001) In vivo up-regulation of aryl hydrocarbon receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a dioxinresistant rat model. Biochem Pharmacol 62:1565-1578.
13. Fuhr U (2000) Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 38:493-504.
14. George J, Murray M, Byth K, and Farrell GC (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120-128.
15. Ghosal A, Sadrieh N, Reik L, Levin W, and Thomas PE (1996) Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Arch Biochem Biophys 332:153-162.
16. Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256:1189-1194.
17. Hewitt NJ, Lecluyse EL, and Ferguson SS (2007) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224.
18. Hoyumpa AM, Jr and Schenker S (1982) Major drug interactions: effect of liver disease, alcohol, and malnutrition. Annu Rev Med 33:113-149.
19. Huss JM and Kasper CB (2000) Two-stage glucocorticoid induction of CYP3A23 through both the glucocorticoid and pregnane X receptors. Mol Pharmacol 58:48-57.
20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, and MacSween RN, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699.
21. Jan YH, Mishin V, Busch CM, and Thomas PE (2006) Generation of specific antibodies and their use to characterize sex differences in four rat P450 3A enzymes following vehicle and pregnenolone 16alpha-carbonitrile treatment. Arch Biochem Biophys 446:101-110.
22. Jiko M, Yano I, Okuda M, and Inui K (2005) Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. Pharm Res 22:228-234.
23. Jiménez W, Clária J, Arroyo V, and Rodés J (1992) Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 7:90-97.
24. Kobayashi K, Urashima K, Shimada N, and Chiba K (2002) Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889-896.
25. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
26. Li H and Letcher RJ (2002) A high-performance-liquid-chromatography-based method for the determination of hydroxylated testosterone metabolites formed in vitro in liver microsomes from gray seal (Halichoerus grypus). J Chromatogr Sci 40:397-402.
27. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
28. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, and Watkins PB (1992) The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51:229-238.
29. Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, and Nef P (1997) Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337:62-68.
30. Marshall WJ and McLean AE (1969) The effect of cirrhosis of the liver on microsomal detoxications and cytochrome P-450. Br J Exp Pathol 50:578-583.
31. Morgan DJ and McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 29:370-391.
32. Murray GI, Melvin WT, Greenlee WF, and Burke MD (2001) Regulation, function, and tissuespecific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41:297-316.
33. Murray M (1999) Induction and inhibition of CYPs and implications for medicine. Mol Aspects Med 20:24-33.
34. Murray M and Butler AM (1996) Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 279:1447-1452.
35. Orlando R, De Martin S, Pegoraro P, Quintieri L, and Palatini P (2009) Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85:319-326.
36. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, and Palatini P (2006) Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 79:489-499.
37. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, and Palatini P (2004) Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 75:80-88.
38. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
39. Palatini P, De Martin S, Pegoraro P, and Orlando R (2008) Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 3:56-69.
40. Palatini P, Orlando R, and De Martin S (2010) The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opin Drug Metab Toxicol 6:1215-1230.
41. Park BK, Kitteringham NR, Pirmohamed M, and Tucker GT (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41:477-491.
42. Pascussi JM, Drocourt L, Fabre JM, Maurel P, and Vilarem MJ (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58: 361-372.
43. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
44. Rosa DP, Bona S, Simonetto D, Zettler C, Marroni CA, and Marroni NP (2010) Melatonin protects the liver and erythrocytes against oxidative stress in cirrhotic rats. Arq Gastroenterol 47:72-78.
45. Segel J (1975) Enzyme Kinetics, John Wiley and Sons, New York.
46. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
47. Singh D, Kashyap A, Pandey RV, and Saini KS (2011) Novel advances in cytochrome P450 research. Drug Discov Today 16:793-799.
48. Turan VK, Mishin VM, and Thomas PE (2001) Clotrimazole is a selective and potent inhibitor of rat cytochrome P450 3A subfamily-related testosterone metabolism. Drug Metab Dispos 29:837-842.
49. Velenosi TJ, Fu AY, Luo S, Wang H, and Urquhart BL (2012) Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease. Drug Metab Dispos 40:1508-1514.
50. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
51. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
52. Wu ZQ, Piché D, Vallières S, Huet PM, and Gascon-Barré M (1991) Unimpaired induction of drug-metabolizing enzymes in hepatocytes isolated from rats with micronodular cirrhosis. Can J Physiol Pharmacol 69:426-436.
53. Yoshinari K, Sato T, Okino N, Sugatani J, and Miwa M (2004) Expression and induction of cytochromes p450 in rat white adipose tissue. J Pharmacol Exp Ther 311:147-154.